Redeye comments on Alzinova’s announcement that the FDA has approved its IND application for ALZ-101. We view this regulatory clearance as an important milestone that enables the company to advance into phase II, strengthening the credibility of the program and paving the way for broader clinical evaluation. The focus now shifts to securing a partnership and financing to ensure the study can commence on schedule.
LÄS MER
